MED12 and non-small cell lung carcinoma: According to previous reports, reduced MED12 expression can lead to TKI resistance in EML4-ALK rearranged NSCLC cell lines (H3122) and EGFR-TKI sensitive cell lines through the regulation of TGF-beta receptor signaling [32].